Deepak Mittal, MD
Nephrology · Florence, KYNPI 1447296538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 26.6% of the total. 2025 is the largest year on record at $1,490, more than ten times the $106 reported in 2019.
Across 266 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Vifor Pharma, Inc.$538
- Amgen$447
- Calliditas Therapeutics US Inc.$434
- Otsuka America Pharmaceutical, Inc.$366
- Fresenius USA Marketing, Inc.$312
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,01398%
- Education$1172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 64 | $1,364 |
| Vifor Pharma, Inc. | 32 | $538 |
| Amgen(2 entities) | 26 | $447 |
| Calliditas Therapeutics US Inc. | 24 | $434 |
| Otsuka America Pharmaceutical, Inc. | 17 | $366 |
| Fresenius USA Marketing, Inc. | 15 | $312 |
| Bayer | 18 | $293 |
| Travere Therapeutics, Inc. | 15 | $228 |
| Novartis | 8 | $210 |
| Novo Nordisk | 6 | $135 |
| Boehringer Ingelheim | 6 | $105 |
| Ardelyx, Inc. | 5 | $97 |
| Aurinia Pharma U.S., Inc. | 4 | $92 |
| Mallinckrodt Hospital Products Inc. | 4 | $88 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Shield Therapeutics Inc | 3 | $54 |
| Akebia Therapeutics Inc | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
| OPKO Pharmaceuticals, LLC | 2 | $37 |
| GSK | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Quanta Dialysis Technologies Inc | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Abiomed | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,130 in reported general payments places this provider in the 80th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 45 | $158,276 |
| FarxigaDapagliflozin Propanediol | 68 | $81,627 |
| Repatha SureclickEvolocumab | 39 | $33,402 |
| OzempicSemaglutide | 21 | $24,589 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $22,838 |
| Calcitriol | 445 | $7,983 |
| Sevelamer Carbonate | 32 | $6,977 |
| Hydralazine Hcl | 390 | $5,865 |
| Fosfomycin Tromethamine | 14 | $4,109 |
| Bumetanide | 134 | $3,612 |
| Metoprolol Succinate | 224 | $3,089 |
| Potassium Chloride | 113 | $2,950 |
| Mycophenolate Mofetil | 36 | $2,204 |
| Midodrine Hcl | 41 | $2,178 |
| Spironolactone | 152 | $1,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $312 | $158,27645 claims |
| AstraZenecaFarxiga, Lokelma | $1,364 | $104,46590 claims |
| Novo NordiskOzempic | $135 | $24,58921 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $12 | $73547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Florence
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Sadiq AhmedLexington$17K
- Muhammad FarhanMt Sterling$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.